NCT06692712View on ClinicalTrials.gov

Phase 3, Open-label Study to Assess the Efficacy and Safety of a Single Lumbar Intrathecal Administration of MELPIDA in Individuals with Hereditary Spastic Paraplegia Type 50 (SPG50) Versus Matched Prospective Concurrent Controls.

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

February 28, 2032

Study Completion Date

June 1, 2032

Conditions
Hereditary Spastic Paraplegia Type 50
Interventions
GENETIC

MELPIDA

Gene Therapy agent

Sponsors
All Listed Sponsors
lead

Elpida Therapeutics SPC

INDUSTRY

NCT06692712 - Phase 3, Open-label Study to Assess the Efficacy and Safety of a Single Lumbar Intrathecal Administration of MELPIDA in Individuals with Hereditary Spastic Paraplegia Type 50 (SPG50) Versus Matched Prospective Concurrent Controls. | Biotech Hunter | Biotech Hunter